The FDA has approved a groundbreaking new therapy for patients battling late-stage melanoma, offering hope when options run out.

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026. Click ...

A researcher at the Sumatera Institute of Technology in Lampung has identified a compound in the mulberry plant with ...

Although deaths from cancer have gone down over the last couple decades, the disease remains one of the leading causes of death in the United States, just as it has for the last 75 years, according to ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

NSC51349 selectively inhibits cutaneous HPV replication by targeting viral E2 activity, potentially paving the way for first ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Our large observational study adds long-term survival to the mounting data supporting the use and safety of conservative surgery for low-risk, early-stage cervical carcinoma,” the researchers wrote.

Substandard cancer medications threaten patient safety across sub-Saharan Africa due to poor regulation and oversight.

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...

Melanoma is a type of aggressive skin cancer that is the fifth most deadly cancer. Surgery, immunotherapy and chemo are the typical treatments. But now, the FDA has approved a groundbreaking new ...